George L. Sing - 02 Nov 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Nov 2026, 16:11:39 UTC
Prior SEC filing
06 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ George L. Sing
Filing notes and source

Key filing fact

George L. Sing filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 04 Nov 2026.

Key facts

  • This page summarizes George L. Sing's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
  • 13 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 04 Nov 2026, 16:11.

Change

  • Previous filing in this sequence was filed on 06 Jan 2026.
  • Current net transaction value: -$20,376,358.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001225471 Primary reporting owner

SING GEORGE L

Relationship
Director
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN
Signature
/s/ George L. Sing
Signature date
04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Options Exercise

Transaction value
Shares
+7,830
Change %
+25%
Price
$376.69*
Shares after
38,837
Date
02 Nov 2026
Ownership
Direct
REGN transaction

Common Stock

Options Exercise

Transaction value
Shares
+7,439
Change %
+19%
Price
$380.95*
Shares after
46,276
Date
02 Nov 2026
Ownership
Direct
REGN transaction

Common Stock

Sale

Transaction value
-$1,175,738
Shares
-1,224
Change %
-2.6%
Price
$960.57
Shares after
45,052
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1
REGN transaction

Common Stock

Sale

Transaction value
-$519,399
Shares
-540
Change %
-1.2%
Price
$961.85
Shares after
44,512
Date
02 Nov 2026
Ownership
Direct
Footnotes
F2
REGN transaction

Common Stock

Sale

Transaction value
-$2,427,702
Shares
-2,522
Change %
-5.7%
Price
$962.61
Shares after
41,990
Date
02 Nov 2026
Ownership
Direct
Footnotes
F3
REGN transaction

Common Stock

Sale

Transaction value
-$4,179,533
Shares
-4,338
Change %
-10%
Price
$963.47
Shares after
37,652
Date
02 Nov 2026
Ownership
Direct
Footnotes
F4
REGN transaction

Common Stock

Sale

Transaction value
-$2,575,402
Shares
-2,670
Change %
-7.1%
Price
$964.57
Shares after
34,982
Date
02 Nov 2026
Ownership
Direct
Footnotes
F5
REGN transaction

Common Stock

Sale

Transaction value
-$6,828,133
Shares
-7,073
Change %
-20%
Price
$965.38
Shares after
27,909
Date
02 Nov 2026
Ownership
Direct
Footnotes
F6
REGN transaction

Common Stock

Sale

Transaction value
-$1,470,663
Shares
-1,522
Change %
-5.5%
Price
$966.27
Shares after
26,387
Date
02 Nov 2026
Ownership
Direct
Footnotes
F7
REGN transaction

Common Stock

Sale

Transaction value
-$1,005,753
Shares
-1,040
Change %
-3.9%
Price
$967.07
Shares after
25,347
Date
02 Nov 2026
Ownership
Direct
Footnotes
F8
REGN transaction

Common Stock

Sale

Transaction value
-$194,036
Shares
-200
Change %
-0.79%
Price
$970.18
Shares after
25,147
Date
02 Nov 2026
Ownership
Direct
Footnotes
F9
REGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
750
Date
02 Nov 2026
Ownership
by Spouse
REGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
400
Date
02 Nov 2026
Ownership
by Spouse/Cust Son
REGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,000
Date
02 Nov 2026
Ownership
by Trust for Son

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

REGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-7,830
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,830
Exercise price
$376.69
Footnotes
F10
REGN transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-7,439
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,439
Exercise price
$380.95
Footnotes
F10
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

Represents volume-weighted average price of sales of 1,224 shares of Company stock on November 2, 2026 at prices ranging from $960.03 to $960.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F2

Represents volume-weighted average price of sales of 540 shares of Company stock on November 2, 2026 at prices ranging from $961.76 to $961.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F3

Represents volume-weighted average price of sales of 2,522 shares of Company stock on November 2, 2026 at prices ranging from $962.07 to $962.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F4

Represents volume-weighted average price of sales of 4,338 shares of Company stock on November 2, 2026 at prices ranging from $963.00 to $963.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F5

Represents volume-weighted average price of sales of 2,670 shares of Company stock on November 2, 2026 at prices ranging from $964.10 to $964.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F6

Represents volume-weighted average price of sales of 7,073 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F7

Represents volume-weighted average price of sales of 1,522 shares of Company stock on November 2, 2026 at prices ranging from $966.02 to $966.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F8

Represents volume-weighted average price of sales of 1,040 shares of Company stock on November 2, 2026 at prices ranging from $967.00 to $967.26. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F9

Represents volume-weighted average price of sales of 200 shares of Company stock on November 2, 2026 at prices ranging from $970.16 to $970.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

Footnote F10

The stock option vested in three equal annual installments, commencing one year after the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .